Clinical Trials
30 trialsD07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
InnoPharmax Inc.
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
AstraZeneca
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations
TransThera Sciences (Nanjing), Inc.
Adjuvant Chemotherapy for BTC Based on 3D-PTA
Fudan University
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
KEYVIBE-005
Merck Sharp & Dohme LLC
Neoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical Resection
Meng Chao Hepatobiliary Hospital of Fujian Medical University
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
ACTICCA-1
Universitätsklinikum Hamburg-Eppendorf
PURITY
Gruppo Oncologico del Nord-Ovest
ACHIEVE
The First Affiliated Hospital with Nanjing Medical University
PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery
Shanghai Zhongshan Hospital
Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma
Asan Medical Center
Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence
Fudan University
SCRCA
Henan Cancer Hospital
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
National Institutes of Health Clinical Center (CC)
Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma
Herlev Hospital
Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma
Vejle Hospital
AdBTC-1
Tianjin Medical University Cancer Institute and Hospital
S1310
National Cancer Institute (NCI)
Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery
City of Hope Medical Center
A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts
Roswell Park Cancer Institute
GOC-B-P
Vejle Hospital
Study of Hepatic Arterial Infusion to Treat Biliary Tract Carcinomas
Peking University
Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation
Stanford University
Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma
Fudan University
Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma
Shanghai Zhongshan Hospital
Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor)
University of California, San Francisco
Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma
Rigshospitalet, Denmark